Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT

M. Šťastná-Marková, E. Hamšíková, P. Hainz, P. Hubáček, M. Kroutilová, J. Kryštofová, V. Ludvíková, J. Musil, P. Pecherková, M. Saláková, V. Šroller, J. Vydra, Š. Němečková

. 2021 ; 9 (11) : . [pub] 20211022

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22001488

BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC). We tested whether the status of BKPyV immunity prior to HSCT could provide evidence for the BKPyV tendency to reactivate. We have shown that measurement of pretransplant anti-BKPyV 1 and 4 IgG levels can be used to evaluate the HC risk. Patients with anti-BKPyV IgG in the range of the 1st-2nd quartile of positive values and with positive clinical risk markers have a significantly increased HC risk, in comparison to the reference group of patients with "non-reactive" anti-BKPyV IgG levels and with low clinical risk (LCR) (p = 0.0009). The predictive value of pretransplant BKPyV-specific IgG was confirmed by determination of genotypes of the shed virus. A positive predictive value was also found for pretransplant T-cell immunity to the BKPyV antigen VP1 because the magnitude of IFN-γ T-cell response inversely correlated with posttransplant DNAuria and with HC. Our novel data suggest that specific T-cells control BKPyV latency before HSCT, and in this way may influence BKPyV reactivation after HSCT. Our study has shown that prediction using a combination of clinical and immunological pretransplant risk factors can help early identification of HSCT recipients at high risk of BKPyV disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22001488
003      
CZ-PrNML
005      
20231102132942.0
007      
ta
008      
220107s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/vaccines9111226 $2 doi
035    __
$a (PubMed)34835157
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Šťastná-Marková, Markéta $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
245    10
$a Pretransplant BK Virus-Specific T-Cell-Mediated Immunity and Serotype Specific Antibodies May Have Utility in Identifying Patients at Risk of BK Virus-Associated Haemorrhagic Cystitis after Allogeneic HSCT / $c M. Šťastná-Marková, E. Hamšíková, P. Hainz, P. Hubáček, M. Kroutilová, J. Kryštofová, V. Ludvíková, J. Musil, P. Pecherková, M. Saláková, V. Šroller, J. Vydra, Š. Němečková
520    9_
$a BK polyomavirus (BKPyV) persists lifelong in renal and urothelial cells with asymptomatic urinary shedding in healthy individuals. In some immunocompromised persons after transplantation of hematopoietic stem cells (HSCT), the BKPyV high-rate replication is associated with haemorrhagic cystitis (HC). We tested whether the status of BKPyV immunity prior to HSCT could provide evidence for the BKPyV tendency to reactivate. We have shown that measurement of pretransplant anti-BKPyV 1 and 4 IgG levels can be used to evaluate the HC risk. Patients with anti-BKPyV IgG in the range of the 1st-2nd quartile of positive values and with positive clinical risk markers have a significantly increased HC risk, in comparison to the reference group of patients with "non-reactive" anti-BKPyV IgG levels and with low clinical risk (LCR) (p = 0.0009). The predictive value of pretransplant BKPyV-specific IgG was confirmed by determination of genotypes of the shed virus. A positive predictive value was also found for pretransplant T-cell immunity to the BKPyV antigen VP1 because the magnitude of IFN-γ T-cell response inversely correlated with posttransplant DNAuria and with HC. Our novel data suggest that specific T-cells control BKPyV latency before HSCT, and in this way may influence BKPyV reactivation after HSCT. Our study has shown that prediction using a combination of clinical and immunological pretransplant risk factors can help early identification of HSCT recipients at high risk of BKPyV disease.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hamšíková, Eva $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Hainz, Petr $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Hubáček, Petr $u Laboratory of Virology, Motol Hospital, 150 06 Prague, Czech Republic
700    1_
$a Kroutilová, Marie $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Kryštofová, Jitka $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Ludvíková, Viera $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Musil, Jan $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Pecherková, Pavla, $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic $d 1980- $7 ctu2013787641
700    1_
$a Saláková, Martina $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic $u Department of Genetics and Microbiology, Faculty of Science, Charles University, 120 00 Prague, Czech Republic $u BIOCEV, Biotechnology and Biomedicine Center of the Academy of Sciences, Charles University, 252 50 Vestec, Czech Republic
700    1_
$a Šroller, Vojtěch $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic $u Department of Genetics and Microbiology, Faculty of Science, Charles University, 120 00 Prague, Czech Republic $u BIOCEV, Biotechnology and Biomedicine Center of the Academy of Sciences, Charles University, 252 50 Vestec, Czech Republic
700    1_
$a Vydra, Jan $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
700    1_
$a Němečková, Šárka $u Institute of Haematology and Blood Transfusion, 128 20 Prague, Czech Republic
773    0_
$w MED00200686 $t Vaccines $x 2076-393X $g Roč. 9, č. 11 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34835157 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220107 $b ABA008
991    __
$a 20231102132937 $b ABA008
999    __
$a ind $b bmc $g 1745499 $s 1152635
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 9 $c 11 $e 20211022 $i 2076-393X $m Vaccines $n Vaccines (Basel) $x MED00200686
LZP    __
$a Pubmed-20220107

Najít záznam

Citační ukazatele

Možnosti archivace